What Researchers Did
Researchers reviewed the molecular mechanisms and clinical trial evidence for hyperbaric oxygen therapy (HBOT) in treating Long COVID.
What They Found
The review found that hyperbaric oxygen therapy (HBOT) improves microcirculation, inhibits inflammation and autoimmune responses, and promotes neurological repair. Clinical trials suggest HBOT helps improve symptom severity, reduce symptom duration, and enhance quality of life for Long COVID patients.
What This Means for Canadian Patients
Canadian patients experiencing Long COVID symptoms may find hyperbaric oxygen therapy (HBOT) to be a beneficial treatment option. This therapy could potentially alleviate symptoms like fatigue and cognitive impairment, improving overall quality of life.
Canadian Relevance
This study has no direct Canadian connection.
Study Limitations
The abstract does not provide specific quantitative data from the reviewed clinical trials, limiting the ability to assess the precise magnitude of HBOT's effects.